我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

血管紧张素Ⅱ受体拮抗剂的基础特性与临床应用(续)(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
1999年第2期
页码:
102-105
栏目:
综述
出版日期:
1999-03-01

文章信息/Info

Title:
-
作者:
徐成斌
北京医科大学人民医院 北京 100044
Author(s):
-
关键词:
-
Keywords:
-
分类号:
-
DOI:
-
文献标识码:
-
摘要:
-
Abstract:
-

参考文献/References

［1］Bauer JH, Reams GP1 The angiotensin Ⅱ type Ⅰ receptor antagonists.A New Class of Antihypertensive Drugs.Arch Intern Med , 1995; 155; 1361～1368.

[2]Williams B, Sweet C, Chung O.AⅡ Receptors: Their significance in cardiovascular function and disease.A summary of symposium 0.European heat house Sophia Antipolis, %28 Feb-1 March,1997.

[3]Timmermans PBMWM,Wong PC,Chiu AT,et al.Angiotensin Ⅱ receptors and angiotensin Ⅱreceptor antagonists.Pharmacol Rev , 1993; 45: 205.

[4]Timmermans PBMWM ,Benfield P, Chiu AT, et al.Angiotensin Ⅱreceptors and functional correlates. Am J Hypertens, 1992;221S.

[5]Criscione L , de Gasparo M ,Buhlmayer P, et al.Pharmacological Profile of Valsartan: a potent orally active nonpeptide antagonist of angiotensin Ⅱ AT-2receptor subtype.Br J Pharmacol, 1993;110 (2) : 761.

[6]Markham A , Karan LG.Valsartan a review of its pharmacology and therapeutic use in essential.Hypertension Drugs, 1997; 54(2) : 299.

[7]Goa KL ,Wagstaff AJ.Losartan potassium a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.Drugs, 1996; 51 (5) : 821.

[8]Lo MW , Goldberg MR,McCrea JB, et al.Pharmacok inetics of losartan, and angiotensin Ⅱ receptor antagonist, and its active metabolite Exp-3174 in humans.Clin Pharmacol Ther, 1995; 58:641.

[9]Gillis JC, Markham A.Irbesartan a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.Drugs, 1997; 54 (6) : 885.

[10]Setting the Standard of A Ⅱantagonism: Losartan, the first of a new classs1 1st international symposium on angiotensin Ⅱ antagonism, London, UK Oct 1.1997.Chainmanship Dr.Victor J.Dzau Merek &co; Inc.1997.

[11]Angiotensin Ⅱ antagonism in the management of cardiovascular disease: Solutions into the nextcentury highlights of a symposium with the european society of hypertension.Milan, Itlan,Italy, June 14-17, 1997.Merck & co, Inc.1997.

[12]Emerging therapy for the treatment of renal disease:A Ⅱ Antagonists.Highlights from a Satellite Symposium Intermational Congress of Nephrology.Sydney, australia,May 25. 1997.Merck & co, Inc.1997.

[13]Clan JCN , Critchley JAJH,Lappe JT, et al1 Randomized, doubleblind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared with felodipine ER in lederly patients with mild to moderate hypertension.J Hum Hypertens,1995; 9: 765.

[14]Gradman AH, Arcuri KE, Goldberg AI, et al.Arandomized placebo-controlled, double-blind,parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension, Hypertensin, 1995; 25: 1345.

[15]Oddou-Stock P, Gatlin M , Kobi P, et al.Comparison of the efficacy of two angiotensin Ⅱ antagonists, valsartan and losartan, in essential hypetension(abstract). Am J Hypertens, 1997; 10 (4) :84A.

[16]Crozier I, Ikram H, Awan N , et al.Losartan in heart failure hemodynamic effects and tolerability.Circulation, 1995; 91: 691.

[17] Pitt B, Segal R,Martinez FA , et al.Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study , ELITE).Lancet, 1997; 349: 747.

[18]Holdaas H, Parving HH.Renal beneficial effects of losartan? Perspectives on A Ⅱ antagonist. Summary of symposium.European Heart house Sophia Antipolis, France.28 Feb-1 March, 1997.

[19]Emerging Theraphy for the Treatment of Renal Disease:A Ⅱ antagonists highlights from a satellite symposium international congress of nephrology, Syndey,Australia.May 25 1997.Merch & co, Inc.1997.

[20]Buter H,Navis G, de Zeeuw D, et al.Renal hemodynamic effects of candesartan in normal and impaired renal function in humans.Kidney Int, 1997; 52 ( supp l 63) : S2185.

备注/Memo

备注/Memo:
(收稿1998-12-27)(续完)
更新日期/Last Update: 1999-03-01